PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer.

ABSTRACT:

Background

Previous studies suggest a potential link between interstitial lung diseases (ILD) and EGFR-TKI use, with proton pump inhibitors (PPIs) possibly affecting EGFR-TKI-associated ILD differently. Our objective is to use the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to explore the potential link between ILD and the combination of PPIs and EGFR-TKI.

Methods

A retrospective examination of adverse event reports in the FAERS database spanning from the initial quarter of 2016 and the fourth quarter of 2023 was conducted. Disproportionality analysis, generalized linear models, and adjusted multivariable logistic regression were employed to assess the occurrence of EGFR-TKI-associated ILD in non-small cell lung cancer (NSCLC) patients rec

SUBMITTER: Wang H 

PROVIDER: S-EPMC11827195 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature